← Back to Search

Virus Therapy

ARCT-165 for COVID-19

Phase 1 & 2
Waitlist Available
Research Sponsored by Arcturus Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up for 7 days following each study vaccination
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of 3 different SARS-CoV-2 vaccines in adults.

Eligible Conditions
  • COVID-19
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~for 7 days following each study vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and for 7 days following each study vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in SARS-CoV-2 full-length spike, RBD, and N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs
Changes in SARS-CoV-2 serum neutralizing levels from before vaccination to each subsequent time point, expressed as GMFRs
GMT ratio (ARCT-021/ARCT-165, ARCT-165/ARCT-154, and ARCT-021/ARCT-154)
+9 more

Trial Design

6Treatment groups
Experimental Treatment
Group I: Study Group 6, Adult Participants Previously Vaccinated randomized to receive ARCT-021Experimental Treatment1 Intervention
Participants will receive one dose of ARCT-021 on Day 1
Group II: Study Group 5, Adult Participants Previously Vaccinated randomized to receive ARCT-154Experimental Treatment1 Intervention
Participants will receive one dose of ARCT-154 on Day 1
Group III: Study Group 4, Adult Participants Previously Vaccinated randomized to receive ARCT-165Experimental Treatment1 Intervention
Participants will receive one dose of ARCT-165 on Day 1
Group IV: Study Group 3, Adult Participants Not Previously Vaccinated to receive ARCT-021Experimental Treatment1 Intervention
Participants will receive one dose of ARCT-021 on Day 1 and one dose of ARCT-021 on Day 29
Group V: Study Group 2, Adult Participants Not Previously Vaccinated randomized to receive ARCT-154Experimental Treatment1 Intervention
Participants will receive one dose of ARCT-154 on Day 1 and one dose of ARCT-154 on Day 29
Group VI: Study Group 1, Adult Participants Not Previously Vaccinated randomized to receive ARCT-165Experimental Treatment1 Intervention
Participants will receive one dose of ARCT-165 on Day 1 and one dose of ARCT-165 on Day 29

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Arcturus Therapeutics, Inc.Lead Sponsor
10 Previous Clinical Trials
22,162 Total Patients Enrolled
5 Trials studying COVID-19
21,926 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are enrollment opportunities still available for this medical trial?

"The clinical trial is presently enrolling participants, as indicated on clinicaltrials.gov; the study was launched on August 30th 2021 and the last modification occurred November 10th 2021."

Answered by AI

To what extent have participants been recruited for this experiment?

"Affirmative. Clinicaltrials.gov denotes that this experiment is actively searching for research volunteers, with 72 participants sought from two different sites since its debut on August 30th 2021."

Answered by AI

What criteria do participants need to meet in order to be included in the research?

"For this clinical trial, 72 volunteers aged between 21 and 80 with a confirmed diagnosis of Covid-19 are needed. The participants must be willing to follow the study's restrictions, provide consent for their participation, attend all visits as required by the protocol; if sexually active they need to adhere to contraception requirements and male/female or transgender individuals are eligible. Additionally, those who were previously vaccinated should have received 2 doses at least 5 months before enrolment in the study."

Answered by AI

Is this medical experiment open to individuals who are under 85 years of age?

"The criteria for eligibility requires that participants must fall within the age range of 21 to 80. Additionally, there are 334 studies specifically catered towards minors and 1453 trials designed for senior citizens."

Answered by AI

Who else is applying?

What state do they live in?
Missouri
What site did they apply to?
Arcturus Investigational Site 201
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

Recent research and studies
clinicaltrials.govStudy
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
2021. "A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05037097.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top